AXQ Capital LP Makes New $289,000 Investment in Kiniksa Pharmaceuticals International, plc $KNSA

AXQ Capital LP bought a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 10,455 shares of the company’s stock, valued at approximately $289,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Franklin Resources Inc. boosted its position in shares of Kiniksa Pharmaceuticals International by 62.2% during the 2nd quarter. Franklin Resources Inc. now owns 108,574 shares of the company’s stock worth $3,004,000 after acquiring an additional 41,632 shares in the last quarter. Hillsdale Investment Management Inc. acquired a new position in Kiniksa Pharmaceuticals International during the second quarter valued at approximately $5,550,000. Catalyst Funds Management Pty Ltd bought a new stake in Kiniksa Pharmaceuticals International during the second quarter worth $493,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Kiniksa Pharmaceuticals International during the second quarter worth $253,000. Finally, Creative Planning acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at $358,000. Institutional investors own 53.95% of the company’s stock.

Insider Buying and Selling

In related news, CAO Michael R. Megna sold 50,490 shares of the company’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $38.87, for a total value of $1,962,546.30. Following the sale, the chief accounting officer directly owned 27,046 shares in the company, valued at $1,051,278.02. This represents a 65.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Sanj K. Patel sold 97,390 shares of the firm’s stock in a transaction that occurred on Wednesday, October 22nd. The stock was sold at an average price of $38.83, for a total transaction of $3,781,653.70. Following the transaction, the chief executive officer owned 111,794 shares of the company’s stock, valued at approximately $4,340,961.02. The trade was a 46.56% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 622,513 shares of company stock valued at $23,607,641. Corporate insiders own 53.48% of the company’s stock.

Wall Street Analysts Forecast Growth

KNSA has been the subject of a number of research analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. TD Cowen started coverage on Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a “buy” rating and a $60.00 target price on the stock. Wells Fargo & Company boosted their target price on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research note on Thursday, September 25th. Wedbush reissued an “outperform” rating and issued a $48.00 target price (up previously from $44.00) on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, October 28th. Finally, Citigroup lifted their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and an average price target of $52.00.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA opened at $41.97 on Tuesday. Kiniksa Pharmaceuticals International, plc has a 52 week low of $17.82 and a 52 week high of $42.93. The firm has a market cap of $3.18 billion, a PE ratio of 93.27 and a beta of 0.16. The firm’s fifty day moving average is $38.53 and its 200-day moving average is $33.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). The company had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The business’s revenue for the quarter was up 61.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.18) earnings per share. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.